Wyeth

Warner-lambert Company

Mcneil Ab

Mcneil-ppc, Inc.

Mcneil Consumer Products Company

Galen W Radebaugh

Syed Muzafar Shah

Tianmin Zhu

Sreenivasulu Megati

Christian Ofslager

John Lokhnauth

Huyi Zhang

Charles Melucci

Steven R Fabian

Nataliya Bazhina

Robert Glinecke

Niketa Patel

Jan Szeliga

George Joseph Donato, Iii

Thomas N Julian

Surendra C Mehta

John L Murtha

Mahdi B Fawzi

Hua-pin Huang

Amal Boctor

Scott C Wootton

Suresh R Babu

The present invention provides a compound of formua I: wherein X, R, and Rare as defined herein, and compositions thereof.

Peripheral opioid receptor antagonists and uses thereof

The present invention provides a compound of formula I: wherein X, R, and Rare as defined herein, and compositions thereof.

An ultra-pure, clear thrombin solution having a high specific activity is described as well as a method of manufacture.

Process for preparing an ultra-pure thrombin preparation

A pharmaceutical sustained release homogeneous tablet or homogeneous tablet layer is formed by making a wet granulation using povidone (PVP) in alcohol as the granulating fluid which is mixed with a pharmaceutical active, ethylcellulose, a wicking agent, e.g. microcrystalline cellulose, an erosion promoter, e.g. pregelatinized starch, then drying and milling the granulation and blending with a dry powdered erosion promotor, wicking agent, lubricant, e.g. magnesium stearate and glidant, e.g. silicon dioxide, and compressing the resultant granulation, which upon administration results in a long-lasting slow and relatively regular incremental release of the pharmaceutical active, and multi-layered pharmaceutical active tablets comprising immediate release and/or sustained release layers.

Pharmaceutical sustained release matrix

Solid compositions of certain cholinergic compounds are stabilized in starch. Especially compositions of corn starch combined or mixed with the 0-substituted-1,2,5,6-tetrahydro-3-pyridine oxime ether, CI-979 HCl, a cognition activator, have been found stable in a heated environment of up to 60.degree. C. over 17 days such that no losses were detected by HPLC analysis. A solid peroral pharmaceutical formulation for the treatment of cognitive disorders is based on the bicomponent composition of active ingredient and stabilizer using appropriate amounts of other excipients or components known in the formulation art.

Starch stabilized o-substituted tetrahydropyridine oxime cholinergic

Ultra-pure thrombin preparation

A solid composition for stabilizing the dosage of cognition activator CI-979 HCl by formation of a complex with cyclic polydextrose. In particular, compositions with HP.beta.CD have been found to stabilize CI-979 HCl even in the presence of other excipients such as sodium carbonate. Pharmaceutical formulations for the treatment of cognitive disorders in humans are based on the stabilizing composition of CI-979 HCl and cyclic polydextrose, including appropriate amounts of other excipients or components as known in the formulation art.

Neutral stabilization complex for CI-979 HCl, a cognition activator

Calcium lactate antibacterial complexes in parenteral dosage forms are provided that are relatively free from tissue irritation following injection, comprising a quinolone or naphthyridine.

Soluble calcium lactate antibacterial complexes as non-irritating

A process for the manufacture of purified thromboplastin used in the manufacture of an ultra-pure, clear thrombin solution is described.

Process for purified thromboplastin for ultra-pure thrombin preparation

Pharmaceutical sustained release matrix and process

Growing community of inventors

Chester, NJ, United States of America

Galen W Radebaugh